Project Grant K99CA315586
Award Date 7/15/26
Completion Date 6/30/28
Dollars Obligated $137K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Farmington, CT 06032, USA
Similar Awards
- Federal Grant Award Summary The National Cancer Institute awarded The Jackson Laboratory a $543,984 Project Grant under the Cancer Biology Research program (CFDA 93.396) effective June 1, 2026, through May 31, 2031, to investigate the role of ZBTB7A in acute myeloid leukemia (AML) differentiation. The award funds in vivo animal studies using NSG-SGM3 mice and patient-derived xenografts to evaluate AML engraftment, disease progression, and therapeutic response—outcomes that cannot be adequately...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The Jackson Laboratory a $704,636 Project Grant under the Cancer Biology Research program (CFDA 93.396) on May 14, 2026, for research titled "Pre-Leukemic Hematopoietic Stem Cell Clonal Selection by the Adaptive Immune System." This five-year project, concluding April 30, 2031, will deliver fundamental research on the mechanisms by which the adaptive immune system detects and selects hematopoietic stem and...
- Federal Project Grant Award Summary The Jackson Laboratory received a $452,458 Project Grant from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396) beginning August 1, 2026 and extending through July 31, 2029. The award funds development and validation of enhanced tools for single-cell long-read sequencing isoform transcriptomics (SCLRSEQ) to enable robust mapping and analysis of full-length spliced transcriptional isoforms at single-cell resolution in...
- Federal Project Grant Award Summary The National Cancer Institute awarded a Project Grant of $495,715 to the Sloan-Kettering Institute for Cancer Research under the Cancer Biology Research program (CFDA 93.396) on August 5, 2025, with a completion date of July 31, 2030. This award funds fundamental research to decipher the pathogenesis and therapeutic vulnerabilities in germline RUNX1-mutated acute myeloid leukemia (AML). The research focuses on understanding how germline RUNX1 mutations...
- Federal Project Grant Award Summary The National Cancer Institute awarded $1,034,176 to Sloan-Kettering Institute for Cancer Research under the Cancer Biology Research program (CFDA 93.396) on August 18, 2025, for a project extending through July 31, 2032. The research focuses on understanding and targeting aberrant RNA splicing in leukemia, building on the principal investigator's 13-year track record of discovering genetic alterations in hematopoietic malignancies. The project aims to...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded a $137,631 Project Grant under the Cancer Research Manpower program (CFDA 93.398) to Sloan-Kettering Institute for Cancer Research, effective July 3, 2026, with a completion date of June 30, 2028. This award supports biomedical research training and investigation into the mechanisms by which somatic mutations in RNA splicing factor genes (U2AF1, SF3B1, and SRSF2) drive the development of myelodysplastic syndromes...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded The Johns Hopkins University a $246,660 Project Grant under the Cancer Research Manpower program (CFDA 93.398) on December 27, 2025, with a completion date of June 30, 2028. This award supports Dr. Komatsu's laboratory in conducting translational research to visualize and characterize B cell infiltration and aggregation within the tumor microenvironment. The research employs transgenic mouse models with dorsal skin...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded the Beckman Research Institute of the City of Hope a $517,090 Project Grant under the Cancer Biology Research program (CFDA 93.396) on August 18, 2025, to investigate the role and biological function of a novel signature gene designated AL021978.1 (A978) in Philadelphia chromosome (PH)-positive and PH-like B-cell acute lymphoblastic leukemia (B-ALL). The research aims to address high-risk leukemia subtypes with survival...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded MD Anderson Cancer Center $112,806 through the Cancer Research Manpower program (CFDA 93.398) on December 1, 2025, to support biomedical training and workforce development in cancer research. The award, which extends through April 30, 2028, funds a research training initiative investigating the role of CARM1-mediated methylation of QKI (quaking) protein in glioblastoma stem cell maintenance and tumor development. The project...
- Federal Grant Award Summary Thomas Jefferson University (Sidney Kimmel Medical College) received a $484,405 Project Grant from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396) effective September 1, 2025, through August 31, 2030. This five-year award supports fundamental cancer biology research investigating NSD2 (Nuclear Set Domain Family Member 2) mutations and their role in driving acute lymphoblastic leukemia (ALL) transformation. The research...